585 related articles for article (PubMed ID: 11714839)
21. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
22. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells.
Nohara C; Akiba H; Nakajima A; Inoue A; Koh CS; Ohshima H; Yagita H; Mizuno Y; Okumura K
J Immunol; 2001 Feb; 166(3):2108-15. PubMed ID: 11160262
[TBL] [Abstract][Full Text] [Related]
23. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.
Huang J; Kerstann KW; Ahmadzadeh M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Immunol; 2006 Jun; 176(12):7726-35. PubMed ID: 16751420
[TBL] [Abstract][Full Text] [Related]
24. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers.
Vetto JT; Lum S; Morris A; Sicotte M; Davis J; Lemon M; Weinberg A
Am J Surg; 1997 Sep; 174(3):258-65. PubMed ID: 9324133
[TBL] [Abstract][Full Text] [Related]
25. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
Plautz GE; Mukai S; Cohen PA; Shu S
J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
[TBL] [Abstract][Full Text] [Related]
26. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
[TBL] [Abstract][Full Text] [Related]
27. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
Plautz GE; Touhalisky JE; Shu S
Cell Immunol; 1997 Jun; 178(2):101-7. PubMed ID: 9225000
[TBL] [Abstract][Full Text] [Related]
28. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
Palmer DC; Balasubramaniam S; Hanada K; Wrzesinski C; Yu Z; Farid S; Theoret MR; Hwang LN; Klebanoff CA; Gattinoni L; Goldstein AL; Yang JC; Restifo NP
J Immunol; 2004 Dec; 173(12):7209-16. PubMed ID: 15585842
[TBL] [Abstract][Full Text] [Related]
29. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
[TBL] [Abstract][Full Text] [Related]
30. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
[TBL] [Abstract][Full Text] [Related]
31. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
Kagamu H; Shu S
J Immunol; 1998 Apr; 160(7):3444-52. PubMed ID: 9531305
[TBL] [Abstract][Full Text] [Related]
32. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
[TBL] [Abstract][Full Text] [Related]
33. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
[TBL] [Abstract][Full Text] [Related]
34. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
35. OX-40: life beyond the effector T cell stage.
Weinberg AD; Vella AT; Croft M
Semin Immunol; 1998 Dec; 10(6):471-80. PubMed ID: 9826580
[TBL] [Abstract][Full Text] [Related]
36. Tumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposure.
Wang LX; Plautz GE
J Immunol; 2010 May; 184(10):5612-8. PubMed ID: 20382887
[TBL] [Abstract][Full Text] [Related]
37. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
38. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
39. The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells.
Okamoto T; Harada M; Shinomiya Y; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Mar; 40(3):173-81. PubMed ID: 7728776
[TBL] [Abstract][Full Text] [Related]
40. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]